Pacira BioSciences (PCRX) Proxy filing summary

Executive summary

• Achieved record revenues of $726.4 million in 2025, a 4% year-over-year increase, with net income of $7.0 million and adjusted EBITDA of $186.5 million.

• Treated over 2.5 million patients in 2025, advancing toward the goal of 3 million annually by 2030.

• Advanced the 5x30 strategy, focusing on patient reach, revenue growth, profitability, pipeline expansion, and partnerships.

• Expanded commercial reach through partnerships with Johnson & Johnson MedTech and LG Chem.

• Returned $150 million to shareholders via share repurchases, reducing outstanding shares from 47 million to 41 million.

Voting matters and shareholder proposals

• Election of three Class III directors (Christopher Christie, Samit Hirawat, Thomas Wiggans) to serve until 2029; board recommends voting for these nominees only.

• Ratification of KPMG LLP as independent auditors for 2026.

• Advisory vote to approve executive compensation (Say-on-Pay).

• Approval of amendments to the 2011 Stock Incentive Plan (adding 2.2 million shares) and the 2014 Employee Stock Purchase Plan (adding 800,000 shares).

• Board opposes DOMA Perpetual's three director nominees and urges shareholders to disregard any white proxy cards from DOMA.

Board of directors and corporate governance

• Board consists of nine directors post-meeting, with eight independent members and an independent chair.

• Recent board refreshment: five new independent directors since October 2023, with a sixth nominated for election.

• Annual board and committee self-assessment, majority voting in uncontested elections, and robust risk oversight.

• Board committees include Audit, People & Compensation, Nominating, Governance & Sustainability, Science & Technology, and Transaction Committees.